| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Retrospective Study |
| Article Title |
Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China
|
| Manuscript Source |
Unsolicited Manuscript |
| All Author List |
Dong-Xu Wang, Xu Yang, Jian-Zhen Lin, Yi Bai, Jun-Yu Long, Xiao-Bo Yang, Samuel Seery and Hai-Tao Zhao |
| ORCID |
|
| Funding Agency and Grant Number |
| Funding Agency |
Grant Number |
| International Science and Technology Cooperation Projects |
2016YFE0107100 |
| Capital Special Research Project for Health Development |
2014-2-4012 |
| Beijing Natural Science Foundation |
L172055 |
| Beijing Natural Science Foundation |
7192158 |
| National Ten-thousand Talent Program, the Fundamental Research Funds for the Central Universities |
3332018032 |
| CAMS Innovation Fund for Medical Science (CIFMS) |
2017-I2M-4-003 |
| CAMS Innovation Fund for Medical Science (CIFMS) |
2018-I2M-3-001 |
|
| Corresponding Author |
Hai-Tao Zhao, MD, Professor, Department of Liver Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No. 1, Shuaifuyuan, Wangfujing, Beijing 100730, China. zhaoht@pumch.cn |
| Key Words |
Lenvatinib; Real-world study; Hepatocellular carcinoma; Efficacy; Safety; Treatment |
| Core Tip |
This is a real-world study for advanced hepatocellular carcinoma patients treated with lenvatinib monotherapy in China. The majority of patients in this study presented with hepatitis B virus infection. Our analysis of the safety and efficacy of this intervention confirms previous evidence from the phase III REFLECT study. Multivariate analysis of participant characteristics with changes in serum biomarkers and gene sequencing provides a more comprehensive understanding of lenvatinib responses. This new knowledge, even though based on a small sample, has clinical implications and necessitates further research. |
| Publish Date |
2020-08-14 12:33 |
| Citation |
Wang DX, Yang X, Lin JZ, Bai Y, Long JY, Yang XB, Seery S, Zhao HT. Efficacy and safety of lenvatinib for patients with advanced hepatocellular carcinoma: A retrospective, real-world study conducted in China. World J Gastroenterol 2020; 26(30): 4465-4478 |
| URL |
https://www.wjgnet.com/1007-9327/full/v26/i30/4465.htm |
| DOI |
https://dx.doi.org/10.3748/wjg.v26.i30.4465 |
